Neumora logomark
Skip to main content

Our Pipeline

We are building an industry-leading pipeline of programs for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases

Neuro-psychiatry

Neuro-degeneration

Pan-CNS

Target

Indication

Discovery

Preclinical

Phase 1

Phase 2

Navacaprant

(NMRA-140)

KOR Antagonist

" >

Target

Navacaprant

(NMRA-140)

KOR Antagonist

Major Depressive Disorder

21M

Navacaprant

(NMRA-140)

KOR Antagonist

" >

Target

Navacaprant

(NMRA-140)

KOR Antagonist

Bipolar Depression

7M

Target

NMRA-511

V1aR Antagonist

Agitation in Alzheimer’s Disease

6M

Target

NMRA-266

M4 Modulator

Schizophrenia

3M

Target

NMRA – M4R

M4 Modulator

Schizophrenia

3M

NMRA-NMDA

NMDA Modulator

" >

Target

NMRA-NMDA

NMDA Modulator

Schizophrenia

3M

NMRA-CK1δ

CK1δ Inhibitor

" >

Target

NMRA-CK1δ

CK1δ Inhibitor

ALS/Alzheimer’s Disease

25K / 6M

Target

NMRA-NLRP3

NLRP3 Inhibitor

Parkinson’s Disease

1M

NMRA-GCASE

GCASE Activator

" >

Target

NMRA-GCASE

GCASE Activator

Parkinson’s Disease

1M